The global genital warts (condyloma acuminatum) market is expected to reach a valuation of US$ 1.87 Billion in 2023 and is projected to increase to US$ 3 Billion by 2033, with a CAGR of 4.84%. The dynamics of the genital warts market are expected to change in the coming years owing to the expected launch of emerging drugs. Key players, such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others, are developing drugs for genital warts. Moreover, successful, and well-communicated vaccination programs have increased public knowledge of vaccines and their advantages, resulting in greater vaccine uptake. In addition, increased vaccination coverage has been linked to a lower occurrence of genital warts.
Factors such as the rise in the prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections and growth in the male population are further anticipated to boost the overall growth of the genital warts treatment market within the forecast period. Furthermore, the genital warts market is fuelled by the increasing availability of therapies developed for self-target applications.
Additionally, the quadrivalent HPV vaccination has been proven to prevent genital warts and cervical cancer. The effectiveness of Imiquimod topical administration may be boosted by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a stronger therapeutic response than vaccination.
Moreover, the therapeutics landscape and genital warts market expects more patient-applied modalities that provide the simplicity of application, safety, and the benefit of self-administration. The rising incidence of various malignancies underlines the disparity in exposure and risk factors between genital wart patients and the general population. The paucity of effective data and alternate treatment regimens makes it challenging for doctors to deliver the appropriate treatment when initial treatments fail. Thus, all the factors mentioned above act as an obstruction to the growth of the genital warts market.
Lack of awareness about the diagnosis & treatment of such diseases and the high cost of treatment are some factors restricting growth. There is a high unmet need for targeted drugs with enhanced clinical profiles at low costs and convenient administration schedules. However, increasing Research and Development expenditure on oncologic diseases offers a promising future for the market in the foreseeable future.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 1.87 Billion |
| Anticipated Forecast Value (2033) | US$ 3 Billion |
| Projected Growth Rate (2023 to 2033) | CAGR 4.84% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global industry for Genital Warts was valued at around US$ 1 billion in the historical period while exhibiting a CAGR of 2.02%. The pandemic negatively affected the market but noteworthy growth was witnessed during the post-pandemic period.
Moreover, the increasing availability of therapies developed for self-target applications and the use of physical destruction treatment therapies such as Cryotherapy and other chemical treatments in treating Genital warts have augmented market growth. Considering these factors, FMI has projected the market to grow at a CAGR of 4.84%, while reaching a valuation of US$ 3 Billion by end of the forecast period.
Emerging therapies to propel the Market Growth
The genital warts market is fuelled by the increasing availability of therapies developed for self-target applications. Additionally, the quadrivalent HPV vaccination has been proven to prevent genital warts and cervical cancer. The effectiveness of Imiquimod topical administration may be boosted by concurrently using an IL-10 inhibitor, attracting more T-cells and destroying HPV-infected keratinocytes of genital warts, evoking a stronger therapeutic response than vaccination
Additionally, the growing focus of pharmaceutical manufacturers on the development of therapeutics that can be administered by the patient themselves and growing levels of availability for therapeutics designed for target applications/indications of HPV globally will also augment the genital warts treatment market in the forecast period.
Also, increasing research and development for therapies and treatments are to further extend suitable prospects for the growth of the genital warts treatment market in the near future.
Principal Consultant
Unawareness and complications regarding vaccines and therapies hinder the growth
The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that restrict genital warts market growth. In addition, current treatments for genital warts are mostly ablative or topical administrations of Imiquimod cream and Sinecatechins (Polyphenon E) ointment, but major issues with low patient compliance and high recurrence rates have been noted due to systemic adverse effects.
Furthermore, due to the length of time required for successful treatment and high recurrence rates, the present genital warts treatment paradigm, which includes manual excision of warts, is far from optimum. Patients with genital warts are more prone to develop HPV-related cancers, particularly anogenital malignancies, thus hampering the growth of this market.
The complications linked with the utilization of vaccines and therapeutics for the HPV virus might hamper the market’s growth which can be one of the challenging factors within the forecast period. Existing treatment procedures are often painful or invasive, and can have undesirable outcomes such as scarring or dyspigmentation that often requires repeat visits. This results in a decrease in the diagnostic rate, which in turn, is likely to restrain the genital warts therapeutics market.
Furthermore, there are no specific treatments available for genital warts. The most commonly used treatments are cauterization and freezing. On the other hand, topical skin medications that are generally prescribed for the treatment of warts are commonly prescribed for skin conditions and skin cancers as well. These aforementioned factors will hold back the market expansion.
In terms of revenue, North America dominated the genital warts market with a market share of 40% followed by Europe. the market is growing with a CAGR of 4.2% in the forecast period of 2023 to 2033 and is expected to attain a valuation of US$ 1.5 Billion by 2033.
Well-established healthcare infrastructure, rising prevalence of STDs and genital warts cases, early adoption of advanced products, and presence of key players are major factors that are anticipated to drive the market in the region. Moreover, focus on research & development by leading players is expected to boost the market.
Asia Pacific region is projected to observe the fastest growth throughout the forecast period. Swift economic development, improvements in healthcare infrastructure, increase in disposable income, and rise in consumer awareness are likely factors that contribute to regional growth.
Emerging economies of China, India, South Korea, and others are anticipated to observe strong growth in the coming years. The market is projected to grow with a CAGR of 4.5% in the forecast period and is expected to reach US$ 900 Million by 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospital pharmacies are expected to capture the largest share among distribution channels by 2033. Hospital pharmacies preserve the stock of products related to HPV-associated disorders like Genital Warts, mainly for outpatients and inpatients.
The segment will be driven by growing consumer awareness and increased investments in healthcare infrastructure across developing and underdeveloped economies.
The chemical treatment segment is expected to dominate the global genital warts therapeutics market, in terms of revenue by 2033. The use of Imiquimod (Aldara, Zyclara), Podophyllin and podofilox (Condylox), Trichloroacetic acid, and Sinecatechins (Veregen) are expected to fuel the market growth of genital warts during the forecast period.
Key players in the Genital Warts market are Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Medicis Pharmaceuticals, Aresus Pharma, AbbVie, Sanofi S.A., AbbVie Inc, Perrigo Company PLC, Glenmark Pharmaceuticals. Some key developments in this market are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 1.87 Billion |
| Market Value in 2033 | US$ 3 Billion |
| Growth Rate | CAGR of 4.84% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023-2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global genital warts market to expand at a 4.84% value CAGR by 2033.
The global genital warts market is expected to garner a market value of US$ 3 Billion by 2033.
FMI has projected North America to be one of the most profitable regions for the Genital Warts market.
APAC region is expected to grow fastest during the forecast period.
1. Executive Summary | Genital Warts (Condyloma Acuminatum) Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Chemical Treatment
5.3.2. Ablative Treatment
5.3.3. Preventive Treatment
5.3.4. Other Treatments
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia & Pacific
7.3.5. East Asia
7.3.6. Middle East & Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The US
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. The UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Australia
11.2.1.6. New Zealand
11.2.1.7. Rest of South Asia & Pacific
11.2.2. By Treatment
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Treatment
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Treatment
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Treatment
14.1.2.2. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Treatment
14.2.2.2. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Treatment
14.3.2.2. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Treatment
14.4.2.2. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Treatment
14.5.2.2. By Distribution Channel
14.6. The UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Treatment
14.6.2.2. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Treatment
14.7.2.2. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Treatment
14.8.2.2. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Treatment
14.9.2.2. By Distribution Channel
14.10. India
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Treatment
14.10.2.2. By Distribution Channel
14.11. Malaysia
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Treatment
14.11.2.2. By Distribution Channel
14.12. Singapore
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Treatment
14.12.2.2. By Distribution Channel
14.13. Thailand
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Treatment
14.13.2.2. By Distribution Channel
14.14. Australia
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Treatment
14.14.2.2. By Distribution Channel
14.15. New Zealand
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Treatment
14.15.2.2. By Distribution Channel
14.16. China
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Treatment
14.16.2.2. By Distribution Channel
14.17. Japan
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Treatment
14.17.2.2. By Distribution Channel
14.18. South Korea
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Treatment
14.18.2.2. By Distribution Channel
14.19. GCC Countries
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Treatment
14.19.2.2. By Distribution Channel
14.20. South Africa
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Treatment
14.20.2.2. By Distribution Channel
14.21. Israel
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2022
14.21.2.1. By Treatment
14.21.2.2. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Treatment
15.3.3. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Verrica Pharmaceuticals
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Tamir Biotechnology
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Novan Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Medicis Pharmaceuticals
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Aresus Pharma
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. AbbVie
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Sanofi S.A.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. AbbVie Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Perrigo Company PLC
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Glenmark Pharmaceuticals
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Genital Warts (Condyloma Acuminatum) Market
